BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

«Fallopian Tube Neoplasms

Below is an extended Fallopian Tube Neoplasms research listing. Click here to return to the Fallopian Tube Neoplasms main in depth entry.

Recent Publications on Fallopian Tube Neoplasms:

Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention.
PURPOSE: A diagnosis of primary peritoneal serous carcinoma (PPSC)...
Direct Link
25th September, 2008
Department of Pathology, Brigham and Women's Hospital, 75 Francis St,
Chromosomal instability in fallopian tube precursor lesions of serous carcinoma and frequent monoclonality of synchronous ovarian and fallopian tube mucosal serous carcinoma.
OBJECTIVES: Pelvic serous carcinomas are classified according to the...
Direct Link
10th September, 2008
Department of Obstetrics and Gynecology, University of British Columbia,
Paclitaxel poliglumex and carboplatin as first-line therapy in ovarian, peritoneal or fallopian tube cancer: a phase I and feasibility trial of the Gynecologic Oncology Group.
PURPOSE: To estimate the maximum tolerated dose (MTD) of paclitaxel...
Direct Link
10th September, 2008
Section of Gynecologic Oncology, Fox Chase Cancer Center, Philadelphia, PA
Does three-dimensional power Doppler ultrasound improve the diagnostic accuracy for the prediction of adnexal malignancy? 5th September, 2008
Department of Perinatology and Gynecology, Kagawa University School of
Primary fallopian tube cancer may mimic endometrial malignancy. 5th September, 2008
Fallopian tube carcinoma. 4th September, 2008
Department of Pathology, Swami Ramanand Teerth Rural Medical College and
Adenofibroma of the fimbria: a common entity that is indistinguishable from ovarian adenofibroma.
Fallopian tube adenofibromas (FTAs) are considered rare, but their...
Direct Link
30th August, 2008
Department of Pathology, Division of Women's and Perinatal Pathology,
Correlation of dermatomyositis with fallopian tube carcinoma: A potential paraneoplastic syndrome.
Fallopian tube adenofibromas (FTAs) are considered rare, but their...
Direct Link
30th August, 2008
Department of Gynaecology Oncology, Metaxa Memorial Cancer Hospital,
Pure multivisceral manifestation of paraneoplastic dermatomyositis mimicked highly disseminated recurrent carcinoma of the fallopian tube.
The safety and maximum tolerated dose (MTD) of erlotinib with...
Direct Link
12th August, 2008
[Surgical treatment of fallopian tube carcinoma with metastases in the pelvic peritoneum, cervix uteri (septum rectovaginale), and the colon transversum] 9th August, 2008
Medical University-Varna, "St. Anna" Municipality Hospital, Clinic of
A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer.
OBJECTIVE: Determine the safety and efficacy of cetuximab plus paclitaxel...
Direct Link
6th August, 2008
Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.
Treatment of recurrent or persistent platinum-refractory ovarian, fallopian tube or primary peritoneal cancer with gemcitabine and topotecan: a phase II trial of the Puget Sound Oncology Consortium.
OBJECTIVE: To determine the nature and degree of toxicity, response rate,...
Direct Link
6th August, 2008
Department of Obstetrics and Gynecology, University of Washington School
Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel.
PURPOSE: Abraxane (ABI-007) is a 130-nm albumin-bound (nab) particle...
Direct Link
1st August, 2008
Clinical Pharmacology Program, Science Applications International
Gene expression profiles of luteal phase fallopian tube epithelium from BRCA mutation carriers resemble high-grade serous carcinoma.
PURPOSE: To identify molecular alterations potentially involved in...
Direct Link
1st August, 2008
Department of Laboratory Medicine and Pathobiology, Division of
A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers.
The safety and maximum tolerated dose (MTD) of erlotinib with...
Direct Link
11th June, 2008
CR-UK Clinical Trials Unit, Beatson Oncology Centre, Western Infirmary,
 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.  See User Agreement

Send comments and feedback to:
Peter Barfoot Managing Director, BioPortfolio Ltd.
UK Tel: (+44) 1300 321501
USA Voicemail and Fax: (+1) 415 680 2472

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2008 - BioPortfolio Limited.

BioPortfolio logo

Valid XHTML 1.0 Transitional